

Adverse Outcomes in Pulmonary Tuberculosis patients on Retreatment Regimen: Evaluation of Pharmacokinetic Estimates as Risk Indicators

Anant Mohan¹, Anuj Bhatnagar², Tarang Gupta¹, Sunita Kanswal¹, Ujjalkumar Das¹,
Thirumurthy Velpandian¹, Randeep Guleria¹ and Urvashi B. Singh^{1*}

¹ All India Institute of Medical Sciences, New Delhi, India

² Rajan Babu Institute of Pulmonary Medicine and Tuberculosis and Hospital, New Delhi, India

***Correspondence to:**

drurvashi@gmail.com

Key words : TDM, ATT, Retreatment regimen, Pharmacokinetics

Abstract

Patients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated on re-treatment regimen. These patients are known to have adverse outcomes. This study aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcome. Plasma levels of retreatment regimen drugs [Isoniazid(INH), Rifampicin(RIF), Pyrazinamide(PZA), Ethambutol(EMB), and Streptomycin(STM)] were compared between treatment responsive/cured and treatment failure/not-cured patients. Plasma drug levels were analysed by LC-MS/MS at different time points in 134 PTB patients on retreatment regimen. Of the 134 subjects, 108 were cured, 17 patients developed multi-drug resistant TB (MDR-TB), and 9 patients remained smear positive at treatment completion (8 months). The two-hour plasma levels (C_{2hr}) (geometric mean) were lower in 'Not Cured' subjects compared to 'Cured' subjects. Notably, in the 26 'Not Cured' subjects, C_{2hr} plasma levels after first dose at Day0 were significantly low (INH: 0.86 vs 2.94 $\mu\text{g/ml}$ $p \leq 0.002$, RIF: 0.56 vs 2.55 $\mu\text{g/ml}$ $p \leq 0.003$, PZA: 1.85 vs 26.58 $\mu\text{g/ml}$ $p \leq 0.000$ and EMB: 0.72 vs 1.53 $\mu\text{g/ml}$ $p \leq 0.010$). In contrast, STM levels were higher (31.84 vs 18.08 $\mu\text{g/ml}$ $p \leq 0.007$). Based on ROC analysis of the data, therapeutic indicator values for successful treatment outcome were C_{2hr} plasma levels of 10.6 $\mu\text{g/ml}$ for PZA, 1.14 $\mu\text{g/ml}$ for RIF, 1.86 $\mu\text{g/ml}$ for INH and 1.24 $\mu\text{g/ml}$ for EMB. Therapeutic failure in PTB patients on retreatment regimen is associated with lower plasma drug levels. Therapeutic drug monitoring would prove useful to maintain drug levels above the minimum cut-off levels for obtaining favourable clinical outcome.

Introduction

In cases of relapse after a successful anti-tubercular therapy (ATT), loss to follow-up or treatment failure, and in others who have undergone previous treatment to TB (1), the standardised retreatment regimen consisting of Isoniazid(INH/H), Rifampicin(RIF/R), Pyrazinamide (PZA/Z), Ethambutol(EMB/E) and Streptomycin(STM/S) for 2 months, followed by HRZE for 1 month and HRE for 5 months (2) is shown to render poor outcomes(3-5) and one of the reasons postulated for this retreatment failure in patients with TB is the sub-therapeutic ATT drug levels or their low bioavailability (6-10) that can lead to slower treatment response, acquired drug resistance, and relapse (11, 12) .

Monitoring of plasma levels of drugs to tailor patient's regimen, in a strategy called as 'Therapeutic Drug Monitoring' (TDM) has shown promising results in reaching requisite treatment goals in PTB patients (13, 14) . Although TDM has been shown to predict clinical outcomes in treatment-naive PTB (12), no study has exclusively monitored drug levels in PTB on a retreatment regimen. TDM may have important implications for improving outcomes in this group of patients. To address this, we evaluated plasma levels of 5 ATT drugs on Day0 (0 and 2hrs after first dose) and after 2, 3, 5 & 8 months of initiation of treatment in subjects who were prescribed PTB retreatment regimen.

Results

Patients, Treatment Regimens and Outcomes: A total of 134 pulmonary TB patients with past history of TB and ATT medication were enrolled in the study. One hundred twenty one (90.3%) patients agreed to the intermittent ATT schedule. (DOTS as per RNTCP guidelines), while 13 (9.7%) preferred the daily regimen. The demographic details and clinical history of the patients is shown in Table 1 and microbiological testing data is shown in Table 2.

All 134 patients had a confirmed drug-susceptible PTB at the start of treatment. Of these, 108 (80.5%) patients were declared cured of TB and classified as 'Cured'. Nine patients (6.72%) were not TB-free as per microbiological testing or physical examination. Seventeen patients (12.7 %) developed Rif resistance (RR) MDR (Multi-drug-resistant TB) by the end of third month of therapy and were referred for MDR regimen. Taken together, these 26 patients were categorized as 'Not Cured'.

Plasma Drug Levels: Plasma levels for H, R, Z, E and S were estimated in all patients for time points day0, followed by month 2, 3, 5 and 8 for H, R, E and day0, 2nd month for Z and on day0 for S.

In the 17 patients who developed RR, plasma levels for H, R, Z, E and S were estimated until 2nd and 3rd month depending on time of MDR diagnosis.

A comparison of drug levels between 'cured' and 'not cured' patient groups according to timelines during the treatment is shown in table 3 and figure 1a. Statistically, plasma levels of isoniazid were significantly higher at 0, 2nd, and 5th month time points, rifampicin levels were significantly higher at day0, comparable at month 2nd and higher at 3rd, 5th and 8th months.

Pyrazinamide and ethambutol levels were significantly higher at both Day0 and 2nd months. In contrast to the above four drugs, streptomycin levels were found to be significantly higher on day0 in the 'Not Cured' category of patients. Of note, all thirteen patients in the study who had been on daily dosing regimen, were cured after the therapy, while all patients who acquired drug resistance or failed treatment had been on intermittent therapy.

Pharmokinetic variability in patient population: Plasma concentrations were found to be widely distributed in the patients. Overall, the highest drug concentrations were attained on day0-C_{2hr} time-point after which most peaks declined with time. Compared to the reference values for adults (15) (16), lower average (GM) drug plasma levels were prevalent at all time points in our study population (Table 3 ,figure 2). 22.3 % (27/121) of patients had plasma concentrations within the reference target range. Only 4/26 'not cured' patients had drug levels within these target ranges and each of these patients achieved 'within range' plasma level for a single drug only.

Area under the ROC curve and predictor values for C_{2hr}plasma ATT levels

Plasma drug levels were significantly lower in 'Not Cured' group when compared to the 'Cured Group' for all ATT drugs at C_{2hr} on day0. Hence we analysed the ROC curves for this time point (Table4, Figure3). The area under the ROC curve were the highest for PZA (0.924) followed by INH (0.788) and RIF (0.77). Optimal cut-off values that predict therapeutic indicator drug levels (minimum levels of drugs that when achieved in patient blood would likely predict a positive treatment outcome) are shown in Table 4. PZA (10.6 µg/ml, 86% sensitivity, 87% specificity) emerged as the best discriminating therapeutic indicator for treatment success in this group of patients (Figure 4).

Discussion

There is a paucity of studies discussing adverse outcomes in PTB re-treatment subjects. Here, we report a serial estimation of levels of first-line ATT drugs measured at five time-points during therapy and correlated to disease outcome exclusively in 134 PTB re-treatment patients.

We found a subject-wise variability in plasma concentrations of all four TB drugs which is in concordance with many other studies.(9, 15). Majority (68.5%) patients had lower drug concentrations than the reference values(15, 16) . In the 'Not Cured' category, C_{2hr} levels of four ATT drugs remained much below reference target ranges for adults almost at all time points during the therapy, and were significantly lower than levels in 'Cured' patients. Patients with extremely low C_{2hr} ATT levels in plasma on day0 had outcomes such as acquired MDR-TB and treatment failure. Post-hoc analysis showed that patients with statistically significant low drug levels (65%) got acquired drug resistance within three months of enrolment in the study. All of these patients had lower levels in comparison to both cured and not cured patients (Figure 1b). No statistically significant difference in the drug plasma levels of patients on daily dose as compared to those on intermittent dosing was evident; however, the plasma levels were higher in daily dose patients (Figure4). A significant increase in microbiologically defined adverse outcomes in patients on intermittent therapy has been previously reported by Johnston et al. where pooled analysis and meta regression showed that intermittent regimen in ATT was inferior in all 3 outcomes viz. failure, relapse and acquired drug resistance (17). WHO has since 2008 recommended daily dosing (2) and country programs too has now implemented daily DOTS therapy (18)

Efficacy of first-line ATT has been shown to strongly associate with area under the curve (AUC). AUC derived from 9-time points sampling during the first 24 hrs post-drug administration were predictive of long-term clinical outcomes in PTB patients (12). Microbicidal effects of ATT are best described by AUC:MIC and C_{max}:MIC ratios (19). Such studies require multiple sampling, are stressful to TB patients and not practical in resource-limited settings. We collected samples at trough concentrations (C₀) and 2 hour concentrations (C_{2hr}) post drug on day 0, months 2, 3, 5 and 8 in order to identify the best indicator time point for single sampling as drug levels at C_{2hr} correlate well with C_{max} and/or AUC (15, 16, 20, 21). However, the possibility that low C_{2hr} plasma concentrations could be a result of delayed absorption rather than a low peak concentration and could miss the actual peak concentration C_{max} (21) cannot be ruled out.

Instead of using predetermined C_{max} concentrations, we first enrolled patients randomly and dichotomized them based on treatment outcomes (clinical with microbiological findings) at the end of the study. Loss to follow-up in a few patients, inability to provide sputum specimens, undetectable plasma drug levels etc. have caused a few gaps in our data. Patients were encouraged to comply and we sought to include all available data for analysis.

Peak drugs levels attained for INH, RIF and PZA reduced with time in our patients in both 'cured' and 'not cured' groups, possibly due to individual pharmacokinetic variations, poor drug absorption, pre-hepatic metabolism and hepatic enzymes induction, drug binding to plasma protein, or drug-drug interactions (22, 23). Rifampicin is reported to be highly bound to plasma proteins in TB patients as well as healthy subjects, leading to a loss in circulating levels, explaining decrease in bioavailability of Rifampicin from 93% to 68% after three weeks of treatment (24-26). It is tempting to hypothesize that drug-drug interaction is at its minimal on

Day0, but may have stronger and complex interactions to compromise drug bioavailability resulting in lower C_{2hr} concentrations subsequently during therapy possibly due to induction of drug metabolism or transporter protein synthesis. Day0- C_{2hr} drug levels for cured patients were higher than subsequent time points except for EMB for which the levels were relatively constant.

We also report *therapeutic indicator levels*, the minimal drug plasma level values predicting a positive treatment outcome (Table 4) for all the four ATT drugs. We believe that the day0- C_{2hr} levels especially that of PZA might be useful as a cut-off reference for dosage adjustments for clinicians during therapy and help mitigate adverse events or treatment failure in DOTS Category II patients early on. Similar to our findings, a recent study where drug exposure and MIC were evaluated in PTB patients, PZA levels were shown to be important in predicting poor clinical response suggesting the use of PZA and RIF at levels above a threshold value to improve treatment outcomes. However, the inter-play between PZA and RIF may affect the final levels detected.(27)

Evaluation of certain other factors which may contribute to patient outcome was beyond the scope of the present study. Improvement in nutritional status and immune response may complement the pharmacotherapy. Low INH concentrations observed in the patients could also be due to the well recognised pharmacogenetic variants with acetylator status (28-30). Another limitation was that we could not delineate the cumulative effects of the drugs or drug–drug interference in the regimen. Our study had some missing data due to missing patient visits (follow-up) and few undetectable drug levels in some patients. These, however, will unlikely impact the overall results obtained.

Overall, we conclude that treatment outcomes in pulmonary tuberculosis patients on retreatment regimen are strongly linked to plasma levels of drugs, with low concentrations leading to poor treatment outcomes. Our findings emphasize the importance of therapeutic drug monitoring and dose adjustment to maintain plasma levels above a critical threshold.

Methods and Materials

Ethics: This study was done at the All India Institute of Medical Sciences (AIIMS), New Delhi, India from 2012-2014 and approved by the Institutional Ethics Committee, AIIMS (IEC/NP-251/2012&RP-22/2012)

Patients : Patients diagnosed with drug susceptible PTB (and no other co-morbidities), aged between 15 to 65 yrs and advised the retreatment regimen under National TB Elimination Program (NTEP) (erstwhile Revised National TB Control Program (RNTCP) were included in this study (31) . Informed written consent was obtained from each patient.

A detailed demographic data and clinical history was obtained (Table 1), and results of sputum acid-fast stains, cultures and all laboratory data were recorded (Table 2). A brief diagram of the study approach is shown in supplementary figure S1.

Treatment Regimen: ATT was given as per the prevailing guidelines of the RNTCP at the time of the study (2012-2014) for previously treated TB cases (erstwhile Category II) i.e., INH + RIF+ EMB + PZA + injectable STM for 2 months, followed by INH + RIF+ EMB + PZA for 1 month , and INH + RIF+ EMB for 5 months as per the weight bands.(H,5mg/Kg , R,10 mg/Kg , Z,30 mg/Kg , E,15 mg/Kg, S,15 mg/Kg(in daily regimen) and H,10 mg/Kg , R,10 mg/Kg , Z,30 mg/Kg , E,15

mg/Kg, S,15 mg/Kg (intermittent regimen). RNTCP followed intermittent regimen recommended by WHO (2),Clinical follow-up of patients was done at 0 day, weeks 2, 4, 8, 12, 20, and 32 (at completion of 8 months). Therapy was not modified during the study.

Sample collection

Sputum samples: For AFB smear, MGIT culture and Xpert MTB/RIF assays, 10 ml sputum sample was collected from study subjects at the time of recruitment (Day0) and at the end of 2, 3, 5 and 8 months.

Blood samples: Half ml blood sample was collected for the measurement of baseline drug concentration just before intake of daily dose of ATT and define the trough of drug level, on all days of sample collection. ATT medicines were given under observation of the field worker before breakfast as prescribed, following which the second blood sample (0.5 ml) was collected at 2 hours from the time of drug intake. Blood samples were collected in polypropylene BD vacuutainers containing EDTA and sodium ascorbate. Separated plasma was stored in plain endotoxin free vials at -80°C for further use.

Samples processing and AFB-staining: Samples were processed for decontamination by Modified Petroff's method and stained for acid fast bacilli by Ziehl-Neelson's staining as per standard protocol (32)

Culture for *Mycobacterium tuberculosis*: Concentrated sediment from decontaminated sample was inoculated in MGIT 960 medium (BD Biosciences) and cultured for *Mycobacterium tuberculosis* (MTB) using standard MGIT™ method as per manufacturer's instructions (Beckton Dickinson, MD, USA)

Xpert MTB/RIF Assay

Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) was used for detection of MTB and resistance to Rifampicin, as per manufacturer's instructions.

LC-MS/MS and $C_{\max}$ determination

Level of drugs in plasma samples were analysed by Liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously (33). An Ultra High Performance Liquid Chromatographic system (UHPLC, Thermo Surveyor system, CITY, USA) coupled with a triple quadrupole mass spectrometer API-4000 QTrap fitted with Turbo Ion Spray Ionization (ESI) source (MDS SCIEX, Applied Biosystems, USA) was operated in positive ion mode for separation and detection of drug concentrations of the anti-tuberculosis drugs (H, R, E, Z and S). Standards were procured from Sigma-Aldrich Ltd, India and the validation of the analytical method was done as per United States Food and Drug Administration (US-FDA) guidelines for bioanalytical method validation (U.S. Food & Drug Administration, 2013).

Pharmacokinetic parameters of C_{0hr} were measured for baseline plasma drug concentration and C_{2hrs} for steady state $C_{\max}$ plasma concentration. The 2-hour plasma concentrations were compared with the reference C_{2hr} concentrations as described previously (15, 16)

Evaluation of Treatment Response: Patients were defined as 'cured' if their sputum were AFB-negative within 5 months of treatment and continued to be negative until the end of treatment along with the physician's clinical assessment of TB free status. 'Not Cured' status was defined as presence of a positive AFB smear beyond 5 months of a compliant tuberculosis treatment, presence of a drug-resistant strain during any point of treatment, or a physician's evaluation of

symptoms and clinical status after 5 months of treatment compared with the status at diagnosis. (31)

Statistical Analysis: Data were recorded and analysed using MS-Excel-2007 and SPSS 22.0 for Windows® (SPSS Inc., Chicago, IL, USA). Chi-square tests were used to investigate any association of patient demography with clinical outcomes. Geometric mean (GM) plasma concentrations between the patients groups were compared using one way ANOVA and Mann Whitney U tests. Receiver operator characteristics (ROC) curves were used to study the discriminatory abilities of ATT plasma levels between the two categories and optimal cut off for therapeutic indicator levels (TIL). All tests were two sided, with $P \leq 0.05$ indicating a statistically significant difference.

Acknowledgement

We are thankful to our patients for the success of this study. We also thank Mr. Ashish Datt Upadhayay, Statistical Assistant, Department of Biostatistics, AIIMS, New Delhi for the ROC curve analysis.

We thank DST-FIST for providing liquid chromatography coupled tandem mass spectroscopy facility for the analysis.

References

1. WHO. 2013; updated Dec 2014 and Jan 2020. Definitions and reporting framework for tuberculosis—2013 revision. World Health Organisation Switzerland, Geneva.

- 256 2. WHO. 2010 (updated 2017). Treatment of Tuberculosis Guidelines, 4th edition
257 Organisation WH, Geneva, Switzerland.
- 258 3. Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo
259 G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R,
260 Elliott AM, Ellner JJ, Smith PG, Mugerwa RD. 2011. Effectiveness of the standard WHO
261 recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a
262 prospective cohort study. PLoS Med 8:15.
- 263 4. Cohen DB, Davies G, Malwafu W, Mangochi H, Joeke E, Greenwood S, Corbett L, Squire
264 SB. 2019. Poor outcomes in recurrent tuberculosis: More than just drug resistance? PLoS
265 One 14.
- 266 5. Sisodia RS, Wares DF, Sahu S, Chauhan LS, Zignol M. 2006. Source of retreatment cases
267 under the revised national TB control programme in Rajasthan, India, 2003. Int J Tuberc
268 Lung Dis 10:1373-9.
- 269 6. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. 1998. Low serum
270 antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113:1178-
271 83.
- 272 7. Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS, Ind PW, McKenna C.
273 1996. Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary
274 tuberculosis. Bmj 313:1543-5.
- 275 8. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow
276 response to tuberculosis treatment in a state control program, Virginia, USA. Emerg
277 Infect Dis 16:1546-53.

- 278 9. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL,
279 Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and
280 pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-
281 infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-94.
- 282 10. Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. 2015. Serum Levels
283 of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
284 Antimicrob Agents Chemother 60:92-8.
- 285 11. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant
286 tuberculosis not due to noncompliance but to between-patient pharmacokinetic
287 variability. J Infect Dis 204:1951-9.
- 288 12. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug
289 concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-73.
- 290 13. Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W,
291 van Soolingen D, Alffenaar JW. 2016. Current status and opportunities for therapeutic
292 drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol
293 12:509-21.
- 294 14. Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di
295 Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and
296 PBMCs. Br J Clin Pharmacol. 2017 May;83(5):1146-1148. doi: 10.1111/bcp.13196. Epub
297 2017 Jan 18.
- 298 15. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs
299 62:2169-83.

16. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. *Antimicrob Agents Chemother* 57:3614-9.
17. Johnston JC, Campbell JR, Menzies D. 2017. Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. *Clin Infect Dis* 64:1211-1220.
18. NTEP (National Tuberculosis Elimination Programme fRNTCP, RNTCP). 2017 March. National Strategic Plan for Tuberculosis: 2017-25 Elimination by 2025. Welfare MoHwF, Ministry of Health with Family Welfare, Nirman Bhawan, New Delhi.
<https://tbcindia.gov.in/WriteReadData/National%20Strategic%20Plan%202017-25.pdf>.
19. Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. *Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy* 29:1468-81.
20. Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG. 2019. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. *Clin Pharmacokinet* 58:1445-1454.
21. Peloquin CA. 1997. Using therapeutic drug monitoring to dose the antimycobacterial drugs. *Clin Chest Med* 18:79-87.
22. Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. 1987. Influence of the enzyme induction by rifampicin on its presystemic metabolism. *Pharmacol Ther* 33:201-4.

- 322 23. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985.
323 Pharmacokinetics of oral and intravenous rifampicin during chronic administration. *Klin*
324 *Wochenschr* 63:1205-11.
- 325 24. Peloquin CA. 2001. Pharmacological issues in the treatment of tuberculosis. *Ann N Y*
326 *Acad Sci* 953:157-64.
- 327 25. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH,
328 Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA,
329 Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A,
330 Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. 2016. Official
331 American Thoracic Society/Centers for Disease Control and Prevention/Infectious
332 Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible
333 Tuberculosis. *Clin Infect Dis* 63:e147-e195.
- 334 26. Boman G, Ringberger VA. 1974. Binding of rifampicin by human plasma proteins. *Eur J*
335 *Clin Pharmacol* 7:369-73.
- 336 27. Zheng X, Bao Z, Forsman LD, Hu Y, Ren W, Gao Y, Li X, Hoffner S, Bruchfeld J, Alffenaar
337 JW. 2020. Drug exposure and minimum inhibitory concentration predict pulmonary
338 tuberculosis treatment response. *Clin Infect Dis* 18.
- 339 28. Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug
340 metabolism. *Annu Rev Pharmacol Toxicol* 37:269-96.
- 341 29. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ,
342 Aarnoutse RE. 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian
343 patients. *Antimicrob Agents Chemother* 57:3208-13.

30. Aarnoutse R. 2011. Chapter 18: Pharmacogenetics of Antituberculosis Drugs, vol vol 40. Basel, Karger.
31. NTEP (National Tuberculosis Elimination Programme frNTCP, RNTCP). 2016. Technical and Operational Guidelines for TB Control in India Directorate General of Health Services MoHaFW, Nirman Bhawan, Central TB Division, New Delhi - 110001.
32. RNCTP. April 2009. Training Manual for Mycobacterium tuberculosis Culture & Drug susceptibility testing. Directorate General of Health Services MoHaFW, Nirman Bhawan, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110011,
33. Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. 2016. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children. Int J Tuberc Lung Dis 20:666-72.

363 **Tables**

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

Table 1: Basic Demographic and Clinical Details of Study Population

Characteristics	Statistics	Total (n*)
Age		
Age (years)	33.5 $\pm$ 12.5 (15-65)	131
Gender		
Male	87 (64.9%)	134
Female	47 (35.1%)	
Retreatment Category		
Relapse	77(57.5%)	
Treatment after Default	18(13.4%)	124
Treatment Failure	10(7.5%)	
Others	19(14.2%)	
Smoking History		
Non Smoker	73(54.5%)	
Ex Smoker	18(13.4%)	117
Smoker	26(19.4%)	
MSI ** - Ex Smokers	219.47 $\pm$ 265.63	
MSI** - Smokers	391.78 $\pm$ 810.34	
Other History		
Alcohol intake	44(32.8%)	116
Family History of TB	19(14.2%)	
Clinical Data –Symptoms		
Cough	98(73.1%)	118
Fever	65(48.5%)	114
Dyspnea	66(49.3%)	117
Expectoration	60(44.8%)	112
Hemoptysis	28(20.9%)	114
Night Sweats	16(11.9%)	111
Weight Loss	91(67.9%)	118
Loss of appetite	90(67.2%)	117
Diarrhea	6(4.5%)	112
BMI*** (mean $\pm$ SD) kg/m ²	17.9 $\pm$ 3.6 (10.6-31.8)	78
ATT schedule during study		
Daily	13(9.7%)	134
Intermittent	121(90.3%)	

Data are presented as absolute numbers, percentage (%) or mean ($\pm$ SD).

*number of data available/recorded

**MSI- Mean Smoking Index –Calculated as multiplication of the average number of cigarettes smoked per day with duration (in years) .

***BMI, Body Mass Index (weight in kilograms divided by the square of the height in meters)

Table 2: PTB DOTS Category II Patients – Microbiological Diagnosis Details

Test	Time Point (month)	Tested (n)	Positive (n)	Negative (n)	MDR (n)
AFB Smear*	0	132 [§]	105 (79.55%)	27(20.45%)	0
	2	83	9 (10.84%)	74(89.16%)	4
	3	79	8 (10.13%)	71(89.87%)	17**
	5	81	26 (32.10%)	55(67.90%)	
	8	47	2 (4.26%)	45(95.74%)	
MGIT Culture***	0	133 [§]	88 (66.17%)	45(33.83%)	

*AFB, acid-fast bacilli

**Cumulative number of patients

***MGIT Mycobacteria Growth Indicator Tube

[§] For One patient MGIT was not done and in two patients AFB smear data was missing

Table 3: Plasma drug levels at 2 hrs post administration of ATT in DOTS category II PTB patients

Drug	Time Point (month)	Cured		Not Cured		p value
		n*	Plasma levels (µg/ml)**	n*	Plasma levels (µg/ml)**	
ISONIAZID	0	87	2.94(0.161-12.80)	17	0.86(0.06-8.27)	0.002 [§]
	2	68	1.56(0.019-9.89)	14	0.58(0.14-3.07)	0.009 [§]
	3	67	1.46(0.0331-12.30)	8	0.55(0.05-4.84)	0.172
	5	51	1.97(0.0934-13.90)	9	0.24(0.00-2.94)	0.031 [§]
	8	36	1.00(0.0352-6.75)	3	0.25(0.02-1.01)	0.283
RIFAMPICIN	0	79	2.55(0.00268-20.20)	16	0.56(0.05-12.70)	0.003 [§]
	2	54	1.26(0.0802-14.80)	9	1.31(0.19-9.01)	0.689
	3	55	1.44(0.0017-23.30)	5	0.29(0.01-1.49)	0.124
	5	46	1.39(0.00384-37.50)	8	0.24(0.04-2.87)	0.144
	8	31	1.32(0.0643-25.50)	3	0.25(0.06-1.68)	0.380
PYRAZINAMIDE	0	88	26.58(1.03-81.60)	15	1.85(0.06-30.50)	0.000 [§]
	2	71	17.72(0.105-181.0)	14	1.01(0.04-6.43)	0.002 [§]
ETHAMBUTOL	0	88	1.53(0.0803-11.80)	17	0.72(0.18-2.15)	0.010 [§]
	2	70	1.47(0.115-18.00)	14	0.66(0.16-2.19)	0.043 [§]
	3	68	1.56(0.0365-19.80)	8	1.11(0.22-5.07)	0.332
	5	53	1.18(0.0676-22.90)	9	0.25(0.03-2.38)	0.137
	8	36	1.56(0.00813-22.50)	3	0.64(0.08-3.26)	0.344
STREPTOMYCIN	0	83	18.08(0.059-73.60)	19	31.84(1.87-100.00)	0.007 [§]

Time point 0 represents day of initiation of therapy.

*number of data available/recorded

** C2hr data from subjects (on intermittent regimen) was log transformed and is presented as the geometric mean along with range (minimum-maximum) in µg/ml

§Values indicate significant differences between cured and not cured groups (P ≤0.05) by one way ANOVA

Table 4. Receiver operator characteristics (ROC) values for plasma levels of ATT in PTB patients on Retreatment regimen

ATT Drug	n	Area under the Curve	[95% CI]	Optimal Cut off * (µg/ml)	Sensitivity	Specificity
ISONIAZID	104	0.788	[0.67-0.90]	1.86	0.71	0.82
RIFAMPICIN	95	0.770	[0.65-0.89]	1.14	0.77	0.75
PYRAZINAMIDE	103	0.924	[0.84-1.00]	10.6	0.86	0.87
ETHAMBUTOL	105	0.712	[0.60-0.83]	1.24	0.60	0.76
STREPTOMYCIN	102	0.684	[0.54-0.83]	38.0	0.63	0.64

Table shows accuracy of area under the curve for C2hr plasma levels of ATT in PTB patients on retreatment regimen

*Optimal cut off values (column 4) or Therapeutic indicator levels (minimum plasma drug concentrations that predict a positive treatment outcome ('Cured') in the study population).

Figure legends

Figure 1: Serum levels (ug/ml) at different time points for Category II retreatment regimen drugs in PTB patients

Figure 1: a). ATT Plasma levels in Cured and Not Cured PTB patient groups. **b)** ATT Plasma levels in Cured, Rifampicin resistant (RR)MDR and Rifampicin sensitive (RS)Not Cured- groups. X axis shows time points of drug administration i.e. day 0, 2 month, 3 month, 5 month and 8 month (0, 2, 3, 5 and 8 - fig1a) or day 0, 2nd month and 3rd month (0, 2 and 3 -fig1b). Y-axis shows geometric mean of plasma drug concentrations ($\mu\text{g/ml}$) of INH, RIF, PZA, EMB and STM as measured by HPLC-MS in patient blood samples after 2hrs of drug ingestion on day 0. Pyrazinamide is shown for 2 months and streptomycin $C_{2\text{hr}}$ levels are shown for day 0 time point as per the treatment regimen.

Solid line shows data from Cured subjects and dotted line shows data from Not-cured patients. + represents therapeutic indicator levels i.e. 0day- $C_{2\text{hr}}$ levels required for a successful treatment outcome from cut off predicted from ROC analysis . Statistical significance is as shown in Table 3.

Figure 2. Pharmacokinetic variability of isoniazid, rifampicin, pyrazinamide and ethambutol in PTB patients on retreatment regimen at Day0- $C_{2\text{hr}}$.

Figure 2. Figure shows the percentage of patients with very low, low and target (high) serum concentrations at $C_{2\text{hr}}$ on Day0 of drug dose administration in 'cured' and 'not cured' groups for isoniazid, rifampicin, pyrazinamide and ethambutol . Values are in comparison to adult reference ranges as reported previously (17) (18)

Target ranges: H- 3–6 µg/ml , R- 8–24 µg/ml , Z- 20-50 µg/ml and E- 2–6 µg/ml (17)

Low plasma concentrations: H < 3µg/ml , R < 8µg/ml , Z < 35 µg/ml and E < 2 µg/ml .

Very low plasma concentrations: H < 1.5µg/ml , R < 4µg/ml , Z < 20 µg/ml and E < 1 µg/ml

(18)

Figure 3: ROC Analysis of ATT drugs in PTB patients on retreatment regimen

Figure 3: Figure shows ROC curve analysis of Day0-C_{2hr} plasma levels of ATT-drugs, isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB) and streptomycin (STM) in PTB patients on retreatment regimen. Values are as given in table 4.

Figure 4: Daily vs intermittent regimen in PTB patients.

Figure 4: Plasma levels of ATT drugs INH, RIF, PZA, EMB and STM at different time points of Daily vs Intermittent/Alternate Day regimen in PTB patients. X axis shows time points of drug administration i.e. day 0, 2 month, 3 month, 5 month and 8 month (0, 2, 3, 5 and 8).Y-axis shows Geometric Mean of plasma drug concentration (µg/ml) as measured by LC-MS in patient blood samples after 2hrs of drug ingestion. Solid line (—●—) represents plasma levels of daily regimen subjects while intermittent regimen patient data is shown by a dashed line (—▲—).* denotes statistical significance $p \leq 0.05$ Pyrazinamide is shown for upto 2 months and streptomycin C_{2hr} levels are shown for Day0

Figure S1: Study Approach:

Figure illustrates a schematic design of the study from patient enrolment until statistical analysis

526 **Figures**

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

Fig 1




Fig 2




Fig 3




Fig 4




Fig S1

